This can be done by exogenous pulsing with a peptide (e.g., Wilms’ tumor 1 [WT1] peptide) [32,33,34,35,36], by pulsing with apoptotic AML cells or lysates [37,38,39,40], by fusing the DCs with leukemic blasts (so-called fusion hybrids) [41,42], or by messenger RNA (mRNA) electroporation [8,43,44,45]. The gene discussed is WT1; the disease is acute myeloid leukemia.